Update in the treatment of non-melanoma skin cancers: the use of PD-1 inhibitors in basal cell carcinoma and cutaneous squamous-cell carcinoma by Dirk Schadendorf, Paolo A Ascierto

Get full text

Melanoma: From Research to Treatment by Paolo A. Ascierto, John M. Kirkwood, Francesco M. Marincola, Giuseppe Palmieri

Get full text

Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716... by Dirk Schadendorf, Caroline Robert, Reinhard Dummer, Luis de la Cruz-Merino, Paolo A Ascierto, John M Kirkwood, Georgina V Long, Jacek Mackiewicz, Richard A Scolyer, Piotr Rutkowski, Jean-Jacques Grob, Jason John Luke, Michele Del Vecchio, Mizuho Kalabis, Adnan Khattak, Matteo S Carlino, Yujie Zhao, Alexander Eggermont, Vanna Chiarion Sileni, Clemens Krepler

Get full text

Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy by Dirk Schadendorf, Celeste Lebbe, Teresa Amaral, Benjamin Weide, Mariaelena Capone, Gabriele Madonna, Lucia Festino, Reinhard Dummer, Domenico Mallardo, Paolo A Ascierto, Piotr Rutkowski, Jason John Luke, Kilian Wistuba-Hamprecht, Mitchell P Levesque, Roberta Turiello, Elva Morretta, Maria Chiara Monti, Rosa Azzaro, Laurence Imhof, Marc Chevrier, Antje Sucker, Aldo Pinto, Silvana Morello

Get full text